Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
Letter to the Editor
2011:77:1;72-74
doi: 10.4103/0378-6323.74996
PMID: 21220889

Treatment of severe nail psoriasis with etanercept

Joana Dias Coelho, Filipa Diamantino, Sara Lestre, Ana Macedo Ferreira
 Department of Dermatology, Hospital dos Capuchos, Lisbon, Portugal

Correspondence Address:
Joana Dias Coelho
Department of Dermatology, Hospital dos Capuchos, Alameda Santo António dos Capuchos, 1169-050 Lisbon
Portugal
How to cite this article:
Coelho JD, Diamantino F, Lestre S, Ferreira AM. Treatment of severe nail psoriasis with etanercept. Indian J Dermatol Venereol Leprol 2011;77:72-74
Copyright: (C)2011 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

Nail involvement is common in psoriasis and has been reported to occur in up to 50% of patients. [1] It can cause significant physical impairment, severe distress and pain. [1],[2] There is a broad spectrum of nail dystrophies associated with psoriasis, ranging from the common pitting and loosening of the nail plate to the less frequent discoloration and splinter hemorrhages seen in the nail bed. [1] It is frequently refractory to treatment and there is no standardized therapy regimen. [3] Etanercept is a fully humanized, soluble tumor necrosis factor (TNF)-alpha receptor approved for the treatment of plaque psoriasis. It has been shown to be safe and to have long-term efficacy for treatment of moderate to severe psoriasis resistant to other modes. Some reports show that etanercept may have significant benefit in the treatment of psoriatic nail disease, although not approved for its treatment (as only manifestation). [1],[2],[3],[4]

We describe two cases of improvement of nail psoriasis with etanercept treatment. The severity of nail psoriasis was based on the Nail Psoriasis Severity Index (NAPSI). [5]

Case 1: A 59-year-old man with a 25-year history of plaque psoriasis, who after one episode of erythroderma and several systemic therapies (acitretin, methotrexate, cyclosporine), entered stabilization of the disease with Psoriasis Area Severity Index (PASI): 5 for the last 13 years. He was referred to our department because of severe nail psoriasis that was causing psychological distress. There was no improvement with topical application and intralesional injection of corticosteroids. All fingernails had psoriatic lesions (onycholysis, subungual hyperkeratosis, pitting and leukonychia) with NAPSI: 56. No symptoms of psoriatic arthritis were present. He was put on etanercept 50 mg twice a week (12 weeks), followed by etanercept 50 mg once a week (36 weeks), with NAPSI: 4 at week 48 (improvement of 92.9% of the nails′ alterations) [Figure - 1].

Figure 1 :(a– c) NAPSI: 56 at week 0 of treatment with etanercept; (d– g) NAPSI: 4 at week 48

Case 2:0 A 43-year-old man with a 15-year history of plaque psoriasis recalcitrant to traditional systemic therapies was put on efalizumab, with significant clinical improvement of cutaneous psoriasis. After 20 months of efalizumab administration, he had PASI:1 but maintained onycholysis, subungual hyperkeratosis and pitting of all fingers (NAPSI: 53). No symptoms of psoriatic arthritis were noted. We decided to switch from efalizumab to etanercept 50 mg twice a week. At week 12, he was placed on a regimen of etanercept 25 mg twice a week. A significant improvement in nail psoriasis was noted after 1 year of etanercept treatment, with NAPSI: 30 at week 48 (56.6% improvement of the nail psoriasis) [Figure - 2].

Figure 2 :(a– c) NAPSI: 53 at week 0 of treatment with etanercept; (d– g) NAPSI: 30 at week 48

In both the patients, treatment was monitored closely. No side effects were present.

Recent studies have revealed that joint pain and nail psoriasis are responsible for impairment in quality of life. Etanercept therapy provided rapid improvement among patients with nail symptoms at baseline. [4]

In our two cases, the patients had been treated with several systemic therapies for psoriasis without improvement of nail manifestations. At week 48 of etanercept treatment, a good response was obtained with NAPSI improvement (92.9% and 56.6%, respectively). Both the patients were very much satisfied with the outcome.

References
1.
Jiaravuthisan M, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007;57:1-27.
[Google Scholar]
2.
Lawry M. Biological therapy and nail psoriasis. Dermatol Ther 2007;20:60-7.
[Google Scholar]
3.
Rallis E, Stavropoulou E, Rigopoulos D, Verros C. Rapid response of nail psoriasis to etanercept. J Rheumatol 2008;35:544-5.
[Google Scholar]
4.
Luger TA, Barker J, Lambert J, Yang S, Robertson D, Foehl J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009;23:896-904.
[Google Scholar]
5.
Rich P, Scher RK. Nail psoriasis severity index: A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206-12.
[Google Scholar]

Fulltext Views
364

PDF downloads
97
Show Sections